Will Pierre Fabre and Array Have Best-In-Class MEK/BRAF Inhibitor?

Updated results from the COLUMBUS trial in BRAF-mutant advanced melanoma presented at ASCO revealed stellar overall survival data for the combination of encorafenib and binimetinib. Rivals Novartis and Roche will have noted that approval in the US is expected before the end of June.

Gears
Pierre Fabre and Array melanoma combo looks a good fit • Source: Shutterstock

Pierre Fabre Group and partner Array Biopharma Inc. are hoping for approvals on both sides of the Atlantic in the near future for their encorafenib and binimetinib combination treatment for melanoma, boosted by more positive data that have just been presented at the American Society of Clinical Oncology annual meeting in Chicago.

The companies announced updated results from the Phase III COLUMBUS trial in BRAF-mutant advanced melanoma which showed median overall survival...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Anticancer

More from Therapy Areas

UCB Follows Fellow European Pharmas With Major US Investment

 
• By 

The Belgian drugmaker is boosting its biologics capacity over the pond.

In Brief: Starton Moves Low-Dose Lenalidomide To Phase IIa For Multiple Myeloma

 

Study to add to safety and tolerability data for infused formulation and may help identify optimal dose for future pivotal trial.

Lilly Looks For Muscle-Sparing Candidates In Pact With Juvena

 
• By 

Deal Snapshot: Including its internal efforts with bimagrumab, Lilly has been seeking a muscle-sparing therapy to complement GLP-1 obesity drugs, such as Zepbound.